OBJECTIVES: Intravenous infusions (IV) vs. subcutaneous injection (SQ) biologic products offer advantages and disadvantages to patients with inflammatory bowel disease (IBD). This study examines potential predictors of IV vs. SQ openness/preference among patients with IBD. METHODS: Patients (n=263) completed a self-administered, web-based questionnaire assessing demographics, health, disease, treatment characteristics, behaviors, and attitudes. Patients included: U.S. adults (aged ≥18) diagnosed with ulcerative colitis (UC; n=140), Crohn’s disease (CD; n=123), receiving immunomodulator treatment, but biologics-naïve. Chi square and t tests compared patients open vs. not open or preferring vs. not preferring IV. Logistic regression models predicted openness and preference as a function of potential predictors. RESULTS: Among all patients (mean age=45.8, 57.1% female, 23.5% minority, and mean years since diagnosis=10.7), 74.2% were open to starting biologics after discussion with their physicians, 64.6% (n=170) were open to IV, and among those, 34.7% (n=59) preferred IV vs. SQ.  Potential predictors of openness to IV included: considering one’s physician’s advice to be very-to-extremely influential for treatment decisions (OR=4.67; 1.87-11.64), male vs. female (OR=2.94; 1.41-6.10), number of emergency room, hospital, and/or physician visits for UC/CD in the past 6 months (OR=1.24; 1.07-1.43), ever experiencing fever as UC/CD sign/symptom (OR=2.81; 1.21-6.52), and awareness of infusion for UC/CD (OR=2.38; 1.10-5.16); intention to delay biologics treatment due to safety perceptions inhibited openness to IV (odds ratio [OR]=0.48; 95% confidence interval [CI]: 0.35-0.66); all p<.03. Potential predictors of preference for IV over SQ included: higher relative openness to office/hospital/medical facility vs. home site of care (OR=5.72: 3.51-9.31), receiving/ever having received infusion (OR=4.11; 1.31-12.95), and detailed discussion of redness/swelling after injection (OR=4.15; 1.29-13.39), all p<.02. CONCLUSIONS: The current study helps inform patient characteristics, attitudes, and disease and treatment history indicating interest in IV biologics treatment, which can help enable shared decisions to best benefit patients with IBD.